# reload+after+2024-01-22 18:47:40.921250
address1§3611 Valley Centre Drive
address2§Suite 300
city§San Diego
state§CA
zip§92130
country§United States
phone§888 969 7879
website§https://www.travere.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Travere Therapeutics, Inc., an integrated biopharmaceutical company, focuses on identifying, developing, and delivering therapies to people living with rare kidney and metabolic diseases. Its approved products include FILSPARI (sparsentan), a once-daily, oral medication is designed to target two critical pathways (endothelin 1 and angiotensin-II) in the disease progression of IgA; and Thiola and Thiola EC (tiopronin tablets) for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
fullTimeEmployees§462
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Eric M. Dube Ph.D.', 'age': 50, 'title': 'President, CEO & Director', 'yearBorn': 1973, 'fiscalYear': 2022, 'totalPay': 1350293, 'exercisedValue': 0, 'unexercisedValue': 1218438}, {'maxAge': 1, 'name': 'Mr. Christopher  Cline C.F.A.', 'age': 39, 'title': 'Chief Financial Officer', 'yearBorn': 1984, 'fiscalYear': 2022, 'totalPay': 634362, 'exercisedValue': 0, 'unexercisedValue': 586866}, {'maxAge': 1, 'name': 'Dr. William E. Rote Ph.D.', 'age': 60, 'title': 'Senior VP and Head of Research & Development', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 733252, 'exercisedValue': 0, 'unexercisedValue': 358587}, {'maxAge': 1, 'name': 'Mr. Peter  Heerma', 'age': 52, 'title': 'Chief Commercial Officer', 'yearBorn': 1971, 'fiscalYear': 2022, 'totalPay': 705618, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Jula  Inrig M.D.', 'age': 48, 'title': 'Chief Medical Officer', 'yearBorn': 1975, 'fiscalYear': 2022, 'totalPay': 815929, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Sandra  Calvin', 'age': 57, 'title': 'SVP, Corporate Controller & Chief Accounting Officer', 'yearBorn': 1966, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Naomi  Eichenbaum', 'title': 'Vice President of Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Elizabeth E. Reed', 'age': 52, 'title': 'Senior VP, General Counsel & Corporate Secretary', 'yearBorn': 1971, 'fiscalYear': 2022, 'totalPay': 696677, 'exercisedValue': 0, 'unexercisedValue': 1564340}, {'maxAge': 1, 'name': 'Ms. Charlotte  Smith', 'title': 'Senior Vice President of Public Affairs', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Casey  Logan', 'title': 'Senior Vice President of Corporate & Business Development', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§5
boardRisk§4
compensationRisk§6
shareHolderRightsRisk§3
overallRisk§4
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.598
priceToSalesTrailing12Months§2.7976167
currency§USD
dateShortInterest§1702598400
forwardEps§-3.14
pegRatio§-0.02
exchange§NGM
quoteType§EQUITY
shortName§Travere Therapeutics, Inc.
longName§Travere Therapeutics, Inc.
firstTradeDateEpochUtc§1352385000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§2b2caaeb-856a-3467-aaca-ee42583023f1
gmtOffSetMilliseconds§-18000000
targetHighPrice§23.0
targetLowPrice§8.0
targetMeanPrice§14.53
targetMedianPrice§12.0
recommendationMean§1.9
recommendationKey§buy
numberOfAnalystOpinions§15
quickRatio§4.685
grossMargins§-0.13196999
ebitdaMargins§-1.14032
trailingPegRatio§None
